CLEIA CA125 evidences: Good analytical performance avoiding "hook effect"

Tumor Biology

Volumn 34, Issue 1, 2013, Pages 387-393

  Falzarano, R ^a   Viggiani, V ^a   Michienzi, S ^a   Colaprisca, B ^a   Longo, F ^a   Frati, L ^a   Anastasi, E ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

CA125 biomarker; Chemiluminescence system; Radioimmunoassay

Indexed keywords

CA 125 ANTIGEN;

ANALYTIC METHOD; ANALYTICAL ERROR; ARTICLE; AUTOMATION; BLOOD ANALYSIS; BLOOD LEVEL; CANCER PATIENT; CHEMILUMINESCENT ENZYME IMMUNOASSAY; CONTROLLED STUDY; DONOR; FEMALE; HOOK EFFECT; HUMAN; INTERMETHOD COMPARISON; ITALY; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CYST; PRIORITY JOURNAL; RADIOIMMUNOMETRIC ASSAY; RELIABILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

EID: 84872761625     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0561-6     Document Type: Article

References (26)

1. C Sturgeon 2002 Practice guidelines for tumor marker use in the clinic Clin Chem 48 1151 1159 12142367 1:CAS:528:DC%2BD38XlslKksLg%3D
2. Duffy MJ. Tumor markers in clinical practice: a review focusing on common solid cancers. Med Princ Pract. 2012. doi: 10.1159/000338393.
3. ES Kilpatrick MJ Lind 2009 Appropriate requesting of serum tumour markers BMJ. 339 b3111 19773324 10.1136/bmj.b3111
4. KS Suh SW Park A Castro H Patel P Blake M Liang, et al. 2010 Ovarian cancer biomarkers for molecular biosensors and translational medicine Expert Rev Mol Diagn 10 8 1069 1083 21080822 10.1586/erm.10.87 1:CAS:528: DC%2BC3cXhsVCjsbbP
5. BW Yin KO Lloyd 2001 Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16 J J Biol Chem 276 29 27371 27375 10.1074/jbc.M103554200 1:CAS:528:DC%2BD3MXlsV2isrg%3D
6. BW Yin A Dnistrian KO Lloyd 2002 Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene Int J Cancer 98 5 737 740 11920644 10.1002/ijc.10250 1:CAS:528:DC%2BD38Xis1Wru7o%3D
7. P Bischof 1993 What do we know about the origin of CA 125? Eur J Obstet Gynecol Reprod Biol 49 93 98 8365529 10.1016/0028-2243(93)90131-U 1:STN:280:DyaK3sznsVWjuw%3D%3D
8. SE Kabawat RC Bast Jr AK Bhan, et al. 1983 Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125 Int J Gynecol Pathol 2 275 285 6196309 10.1097/00004347-198303000-00005 1:STN:280:DyaL2c%2FmtVGntw%3D%3D
9. PL Walker M Crook 2011 Tumour marker requesting in primary care and the role of the laboratory J Clin Pathol 64 5 443 446 21270062 10.1136/jcp.2010. 085357
10. Bast RC, Klug TL, John St E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309(15):883-7.
11. S Pignata, et al. 2011 Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up Ann Oncol 22 8 viii40 viii44 22180398 10.1093/annonc/mdr470
12. A Santillan R Garg ML Zahurak GJ Gardner RL Giuntoli DK Armstrong, et al. 2005 Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range J Clin Oncol 23 36 9338 9343 16361633 10.1200/JCO.2005.02.2582
13. Granato T, Midulla C, Longo F, Colaprisca B, Frati L, Anastasi E. Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer. Tumor Biol. 2012. doi: 10.1007/s13277-012-0381-8.
14. RC Bast FJ Xu YH Yu S Barnhill Z Zhang GB Mills 1998 CA 125: the past and the future Int J Biol Mark 13 4 179 187 1:CAS:528:DyaK1MXivVGlsrY%3D
15. C Midulla L Manganaro F Longo V Viggiani L Frati T Granato, et al. 2012 HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma Tumour Bio 33 5 1291 1298 10.1007/s13277-012-0376-5 1:CAS:528:DC%2BC38XhsVCgtLbI
16. E Anastasi T Granato A Coppa L Manganaro G Giannini S Comploj, et al. 2011 HE4 in the differential diagnosis of a pelvic mass: a case report Int J Mol Sci 12 1 627 632 21340004 10.3390/ijms12010627 1:CAS:528:DC%2BC3MXhs1Gmtb4%3D
17. A Singhal, et al. 2012 Elevation of CA 125 and CA 19-9 in patients with end-stage liver disease Int J Biol Mark 27 2 e147 e151 10.5301/JBM.2012.9139
18. MJ Duffy JM Bonfrer, et al. 2005 CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use Int J Gynecol Cancer 15 5 679 691 16174214 10.1111/j.1525-1438.2005.00130.x 1:STN:280:DC%2BD2Mrgt1Klsw%3D%3D
19. AM Anthony AAM Ermens HLP van Duijnhove, et al. 2000 Dilution protocols for detection of hook effects/prozone phenomenon Clin Chem 46 10 1719 1720
20. LM McShane, et al. 2005 REporting recommendations for tumour MARKer prognostic studies (REMARK) Br J Cancer 93 4 387 391 16106245 10.1038/sj.bjc.6602678 1:CAS:528:DC%2BD2MXnvFymtLo%3D
21. N Osman, et al. 2008 Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre Ir Med J 101 8 245 247 18990955 1:STN:280:DC%2BD1cjis1KhsQ%3D%3D
22. F Hayes Daniel, et al. 2012 A bad tumor marker is as bad as a bad drug: applying scientific principles to tumor biomarker research Am Assoc Cancer Res Educ Book 2012 1 139 141 10.1158/AACR.EDB-12-8432
23. PG Colman U Di Mario A Rabizadeh F Dotta E Anastasi GS Eisenbarth 1988 A prozone phenomenon interferes in islet cell antibody detection: direct comparison of two methods in subjects at risk of diabetes and in insulin dependent diabetics at onset J Autoimmun 1 2 109 117 3075459 10.1016/0896-8411(88)90019-4 1:STN:280:DyaL1Mzgt1elsw%3D%3D
24. Wu JT. Diagnosis and management of cancer using serologic tumor markers. In: Henry JB, editor. Clinical diagnosis and management by laboratory methods. 19th ed. Philadelphia: WB Saunders; 1996. p. 1071.
25. MA Pesce 1993 "High-dose hook effect" with the Centocar CA 125 assay Clin Chem. 39 1347 8504549 1:STN:280:DyaK3s3nvVyltw%3D%3D
26. A Barbati GC Di Renzo EV Cosmi 1993 Hook effect in immunoradiometric assay of CA 125 in peritoneal fluid: evidence of high CA 125 concentrations by a comparative immunoblotting analysis Clin Chem 39 7 1548 1549 8330419 1:STN:280:DyaK3szitFektQ%3D%3D